|
1
|
Broaddus E, Topham A and Singh AD:
Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol.
93:21–23. 2009.
|
|
2
|
Burnier MN, McLean IW, Zimmerman LE and
Rosenberg SH: Retinoblastoma. The relationship of proliferating
cells to blood vessels. Invest Ophthalmol Vis Sci. 31:2037–2040.
1990.PubMed/NCBI
|
|
3
|
Marback EF, Arias VE, Paranhos A Jr,
Soares FA, Murphree AL and Erwenne CM: Tumour angiogenesis as a
prognostic factor for disease dissemination in retinoblastoma. Br J
Ophthalmol. 87:1224–1228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rubin CM, Robison LL, Cameron JD, et al:
Intraocular retinoblastoma group V: an analysis of prognostic
factors. J Clin Oncol. 3:680–685. 1985.PubMed/NCBI
|
|
5
|
Chong EM, Coffee RE, Chintagumpala M,
Hurwitz RL, Hurwitz MY and Chevez-Barrios P: Extensively necrotic
retinoblastoma is associated with high-risk prognostic factors.
Arch Pathol Lab Med. 130:1669–1672. 2006.PubMed/NCBI
|
|
6
|
Falanga A: Thrombophilia in cancer. Semin
Thromb Hemost. 31:104–110. 2005. View Article : Google Scholar
|
|
7
|
Schaffner F and Ruf W: Tissue factor and
PAR2 signaling in the tumor microenvironment. Arterioscler Thromb
Vasc Biol. 29:1999–2004. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van den Berg YW, Osanto S, Reitsma PH and
Versteeg HH: The relationship between tissue factor and cancer
progression: insights from bench and bedside. Blood. 119:924–932.
2012.PubMed/NCBI
|
|
9
|
Khorana AA, Ahrendt SA, Ryan CK, et al:
Tissue factor expression, angiogenesis, and thrombosis in
pancreatic cancer. Clin Cancer Res. 13:2870–2875. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lopez-Pedrera C, Barbarroja N, Dorado G,
Siendones E and Velasco F: Tissue factor as an effector of
angiogenesis and tumor progression in hematological malignancies.
Leukemia. 20:1331–1340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Contrino J, Hair G, Kreutzer DL and
Rickles FR: In situ detection of tissue factor in vascular
endothelial cells: correlation with the malignant phenotype of
human breast disease. Nat Med. 2:209–215. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lwaleed BA and Bass PS: Tissue factor
pathway inhibitor: structure, biology and involvement in disease. J
Pathol. 208:327–339. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee BJ, Kim JH, Woo SH, Kim DH and Yu YS:
Tissue factor is involved in retinoblastoma cell proliferation via
both the Akt and extracellular signal-regulated kinase pathways.
Oncol Rep. 26:665–670. 2011.PubMed/NCBI
|
|
14
|
Kim JH, Kim JH, Yu YS, Kim DH, Kim CJ and
Kim KW: Establishment and characterization of a novel,
spontaneously immortalized retinoblastoma cell line with adherent
growth. Int J Oncol. 31:585–592. 2007.PubMed/NCBI
|
|
15
|
Jun HO, Kim Y, Kwon YW, et al: Wondonin, a
novel compound, inhibits hypoxia-induced angiogenesis through
hypoxia-inducible factor 1 alpha. FEBS Lett. 581:4977–4982. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lim Y, Jo DH, Kim JH, et al: Human
apolipoprotein(a) kringle V inhibits ischemia-induced retinal
neovascularization via suppression of fibronectin-mediated
angiogenesis. Diabetes. 61:1599–1608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Min JK, Cho YL, Choi JH, et al: Receptor
activator of nuclear factor (NF)-kappaB ligand (RANKL) increases
vascular permeability: impaired permeability and angiogenesis in
eNOS-deficient mice. Blood. 109:1495–1502. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schweigerer L, Neufeld G and Gospodarowicz
D: Basic fibroblast growth factor is present in cultured human
retinoblastoma cells. Invest Ophthalmol Vis Sci. 28:1838–1843.
1987.PubMed/NCBI
|
|
19
|
Eliceiri BP, Klemke R, Strömblad S and
Cheresh DA: Integrin alphavbeta3 requirement for sustained
mitogen-activated protein kinase activity during angiogenesis. J
Cell Biol. 140:1255–1263. 1998. View Article : Google Scholar
|
|
20
|
Callander NS, Varki N and Rao LV:
Immunohistochemical identification of tissue factor in solid
tumors. Cancer. 70:1194–1201. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saito T, Koyama T, Nagata K, Kamiyama R
and Hirosawa S: Anticoagulant effects of retinoic acids on leukemia
cells. Blood. 87:657–665. 1996.PubMed/NCBI
|
|
22
|
Zunyan D, Ying H and Sadee W: Growth
factor signaling and resistance to cancer chemotherapy. Curr Topic
Med Chem. 4:1345–1354. 2004. View Article : Google Scholar
|
|
23
|
Cebulla CM, Jockovich ME, Piña Y, et al:
Basic fibroblast growth factor impact on retinoblastoma progression
and survival. Invest Ophthalmol Vis Sci. 49:5215–5221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu J, May L, Milsom C, et al: Contribution
of host-derived tissue factor to tumor neovascularization.
Arterioscler Thromb Vasc Biol. 28:1975–1981. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bluff JE, Brown NJ, Reed MW and Staton CA:
Tissue factor, angiogenesis and tumour progression. Breast Cancer
Res. 10:2042008. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hembrough TA, Swartz GM, Papathanassiu A,
et al: Tissue factor/factor VIIa inhibitors block angiogenesis and
tumor growth through a nonhemostatic mechanism. Cancer Res.
63:2997–3000. 2003.PubMed/NCBI
|
|
27
|
Hembrough TA, Ruiz JF, Papathanassiu AE,
Green SJ and Strickland DK: Tissue factor pathway inhibitor
inhibits endothelial cell proliferation via association with the
very low density lipoprotein receptor. J Biol Chem.
276:12241–12248. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Provencal M, Michaud M, Beaulieu E, et al:
Tissue factor pathway inhibitor (TFPI) interferes with endothelial
cell migration by inhibition of both the Erk pathway and focal
adhesion proteins. Thromb Haemost. 99:576–585. 2008.PubMed/NCBI
|
|
29
|
Kasthuri RS, Taubman MB and Mackman N:
Role of tissue factor in cancer. J Clin Oncol. 27:4834–4838. 2009.
View Article : Google Scholar : PubMed/NCBI
|
